Drugs / varicella vaccine live
varicella vaccine live
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02062502 Comparator | Mar 2014 → Feb 2015 | chickenpox | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | varicella vaccine live | “This study (NCT02062502) evaluated the safety, tolerability, and immunogenicity of VARIVAX™ (VAR, varicella vaccine live) manufactured using a new seed manufacturing process...” PMID 29087781 ↗ Dec 2017 |
| Known as | VAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02062502 ↗ |
| Known as | VARIVAX | “This study (NCT02062502) evaluated the safety, tolerability, and immunogenicity of VARIVAX™ (VAR, varicella vaccine live) manufactured using a new seed manufacturing process...” PMID 29087781 ↗ Dec 2017 |
| Modality | Vaccine | “Varicella virus vaccine live manufactured with the 2007 process” NCT02062502 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT02062502 ↗ |